Polaris Group's (TPE:6550) unit Polaris Pharmaceuticals signed two exclusive regional agreements to commercialize its drug for treating malignant pleural mesothelioma, according to two separate Monday Taiwan Exchange filings.
The first commercialization and channel sales collaboration deal for the drug, dubbed ADI-PEG 20, was signed with Er-Kim Pharmaceuticals. The contract has a term of eight years and covers the EMEA region.
Meanwhile, another commercialization and sales deal was inked with Tabuk Pharmaceutical Manufacturing for the Gulf Cooperation Council market, valid for six years.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。